Metabolomics, microbiota, and in vivo and in vitro biomarkers in type 2 severe asthma: A perspective review

Caruso C.;Colantuono S.;Nicoletti A.;Arasi S.;Firinu D.;Gasbarrini A.;Coppola A.;Di Michele L.

2021-01-01

---

Abstract

Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient; thus, it could be a new approach for the management of severe asthma that considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. Metabolomics is the systematic study of low molecular weight (bio)chemicals in a given biological system and offers a powerful approach to biomarker discovery and elucidating disease mechanisms. In this point of view, metabolomics could play a key role in targeting precision medicine.